WO2023209634 - A DUAL SELECTIVE PI3K DELTA AND GAMMA INHIBITORS AND/OR A SALT-INDUCIBLE KINASE 3 INHIBITOR FOR TREATING SOLID TUMORS
National phase entry is expected:
Publication Number
WO/2023/209634
Publication Date
02.11.2023
International Application No.
PCT/IB2023/054382
International Filing Date
27.04.2023
Title **
[English]
A DUAL SELECTIVE PI3K DELTA AND GAMMA INHIBITORS AND/OR A SALT-INDUCIBLE KINASE 3 INHIBITOR FOR TREATING SOLID TUMORS
[French]
INHIBITEURS DOUBLES SÉLECTIFS DE PI3K DELTA ET GAMMA ET/OU INHIBITEUR DE KINASE 3 INDUCTIBLE PAR UN SEL POUR LE TRAITEMENT DE TUMEURS SOLIDES
Applicants **
RHIZEN PHARMACEUTICALS AG
Grosspetertower, Grosspeteranlage 29
4052 Basel, CH
INCOZEN THERAPEUTICS PVT. LTD.
13th Floor, Manjeera Trinity Corporate, Phase-3, KPHB
Colony, Kukatpally
Hyderabad, Telangana 500072, IN
Inventors
VAKKALANKA, Swaroop Kumar Venkata Satya
c/o Rhizen Pharmaceuticals AG
Grosspetertower, Grosspeteranlage 29
4052 Basel, CH
NAIR, Ajit Mohanchandran
c/o Incozen Therapeutics Pvt. Ltd.,
13th Floor, Manjeera Trinity Corporate, Phase-3, KPHB Colony, Kukatpally
Hyderabad, Telangana 500072, IN
ELESWARAPU, Venkata Satyanarayana
c/o Incozen Therapeutics Pvt. Ltd.
450, M N Science and Technology Park (Formerly Alexandria Knowledge Park)
Turkapally, Shameerpet
Hyderabad 500078, IN
Priority Data
202241025286
29.04.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2145 | |
| EPO | Filing, Examination | 14163 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 11035 |
Total: 28511 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to the use of a dual selective PI3K delta and gamma (PI3K δ/γ) inhibitor, a Salt-Inducible Kinase 3 (SIK3) inhibitor, or a combination thereof, and pharmaceutical compositions containing them for the treatment of solid tumors, such as breast cancer. The present invention also relates to a compound of formula (A) (also known as Tenalisib, (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one), a dual selective PI3K delta and gamma (PI3K δ/γ) inhibitor, or a pharmaceutically acceptable salt thereof, or a compound of formula (M) ((S)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6- yl)amino)propyl)-4H-chromen-4-one), a Salt-Inducible Kinase 3 (SIK3) inhibitor, or a pharmaceutically acceptable salt thereof, or a combination thereof, for the treatment of solid tumors, e.g., breast cancer.[French]
La présente invention concerne l'utilisation d'un inhibiteur double sélectif de PI3K delta et gamma (PI3K δ/γ), d'un inhibiteur de kinase 3 inductible par un sel (SIK3), ou d'une combinaison de ceux-ci, ainsi que des compositions pharmaceutiques les contenant pour le traitement de tumeurs solides, telles que le cancer du sein. La présente invention concerne également un composé de formule (A) (également connu sous le nom de ténalisib, (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophényl)-4H-chromén-4-one), un inhibiteur double sélectif de PI3K delta et gamma (PI3K δ/γ), ou un sel pharmaceutiquement acceptable de celui-ci, ou un composé de formule (M) ((S)-3-(3-fluorophényl)-2-(1-((8-hydroxy-9H-purin-6- yl)amino)propyl)-4H-chromén-4-one), un inhibiteur de kinase 3 inductible par un sel (SIK3), ou un sel pharmaceutiquement acceptable de celui-ci, ou une combinaison de ceux-ci, pour le traitement de tumeurs solides, par exemple, le cancer du sein.